HAL vs IBRX · P/E 9.3, $19.05B cap vs rev $14.7M
Halliburton Company (HAL) versus Immunitybio Inc (IBRX) — a side-by-side from cached financials, not a winner call.
Halliburton Company (HAL) is a oil & gas equipment & services company listed on US.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
HAL does not have a complete income-statement cache yet.
Latest reported IBRX revenue for 2024-12-31 was $14.7M. Net income was -$413.6M. Revenue was up 2270.6% from 2023-12-31 to 2024-12-31. IBRX currently screens at market cap $7.88B.
HAL currently screens at market cap $19.05B and trailing P/E 9.3. IBRX currently screens at market cap $7.88B.
Not investment advice. Open the HAL and IBRX stock pages for the full models.
Not investment advice.